Revenue Guidance with Q3 2008 Forecasts Growth of More Than 40%
NEW YORK and HAIKOU CITY, Hainan, China, Sept. 18 /Xinhua-PRNewswire- FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, announced today that it projects the 3rd Quarter 2008 revenue growth to exceed 40%.
According to recent sales figures, China Pharma is adjusting its projected Q3 revenue growth upwards to between 40% and 45%.
Ms. Zhilin Li, President and CEO of China Pharma, commented, "We are very pleased that the sales this quarter have exceeded our prediction. This reflects the expansion of our sales force and our continued efforts to increase penetration of our distribution network."
Ms Li continued, "The global capital markets are experiencing a downturn, and the Chinese economy is also tending towards a decline. Our share price has suffered, however we are able to take advantage of the company's very stable platform for growth and continue our good performance. We believe revenue and earnings will maintain continued long-term growth and that this is the best reward for investors. We consider this a good opportunity to communicate and share our confidence on the company outlook with our fellow shareholders."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets
off-patent brand bio-pharmaceutical products in China that treat a wide
range of conditions, including, cardiovascular and CNS diseases,
infections, liver disease and other prevalent diseases. Helpson
Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company
headquartered in Haikou City, Hainan province in China, is a wholly owned
subsidiary of China Pharma Holdings. For more information about China
Pharma Holdings, Inc., please visit http:/
|SOURCE China Pharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved